IMBdx is a precision oncology company focused on cancer diagnosis, monitoring, and screening.
The company developed a minimally invasive liquid biopsy technology for cancer detection and progression monitoring from a single blood draw. IMBdx began its research in 2014 and states a goal of making cancer diagnosis more accessible and affordable worldwide.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
AlphaLiquid provides comprehensive tumor genomic profiling, identifies key mutations, and offers personalized treatment options, including matching therapies and relevant clinical trial opportunities.
Source: LinkedIn company description · Retrieved October 13, 2026
CancerDetect detects trace cancer cells remaining after treatment for early relapse detection.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 13, 2026, September 14, 2026, September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, September 21, 2026, September 26, 2026, September 27, 2026, September 28, 2026, September 30, 2026, October 8, 2026 and October 10, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.